CLASS II ONGOING Drug recall · Reported 4 Sep 2024 · FDA Enforcement Report

Indomethacin Extended-Release Capsules, USP, 75 mg recalled

Glenmark Pharmaceuticals Inc., U is recalling Indomethacin Extended-Release Capsules, USP, 75 mg, distributed nationwide in the US. The recall was initiated on 31 Jul 2024 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot#: 17240105, Exp 12/31/2025
NDC68462-325
UPC0368462325605
Quantity recalled2404 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0643-2024
FDA event ID
95075
Recalling firm
Glenmark Pharmaceuticals Inc., U, Mahwah, NJ
Manufacturer
Glenmark Pharmaceuticals Inc., USA
Classification
Class II
Status
Ongoing
Recall initiated
31 Jul 2024
FDA classified
23 Aug 2024
Reported
4 Sep 2024
Type
Voluntary: Firm initiated
Reason category
Potency & Assay

Timeline

31 Jul 2024Recall initiated by company
23 Aug 2024Classified by FDA+23 days
4 Sep 2024Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Dissolution Specifications: below specification results

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Indomethacin Extended-Release Capsules, USP, 75 mg, packaged in a) 60-count bottle (NDC 68462-325-60) and b) 90-count bottle (NDC 68462-325-90), Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Plot No. 2 Phase-2, Pharma Zone, SEZ, Pithampur, Dist-Dhar, Madya Pradesh - 454775, India Mfg Llc. No: 25/9/2010, Manufactured for Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430.

Where it was distributed

Nationwide USA

Nationwide

Questions about this recall

Is Indomethacin Extended-Release Capsules, USP, 75 mg recalled?

Yes. Glenmark Pharmaceuticals Inc., U recalled Indomethacin Extended-Release Capsules, USP, 75 mg on 31 Jul 2024. The recall is Class II and its status is Ongoing. Recall number D-0643-2024.

Why was it recalled?

Failed Dissolution Specifications: below specification results

Which lots are affected?

Lot#: 17240105, Exp 12/31/2025

Where was it sold?

Nationwide USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Glenmark Pharmaceuticals Inc., U

All 141

Other Indomethacin recalls

All 9